Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Pain Palliat Care Pharmacother ; 37(4): 286-297, 2023 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-37702455

RESUMO

Xtampza ER™, an oxycodone extended-release capsule (OERC), was the first long-acting opioid to feature abuse-deterrent properties and various routes of administration without pharmacokinetic alterations. The primary objective of this study was to evaluate changes in reported pain scores after initiation of or rotation to OERC from a previous opioid.  Baseline scores were from patients' outpatient visits immediately before starting OERC and were compared to those at the next two follow-up visits. Secondary objectives identified variables that influenced pain scores. Methods included screening for cancer patients with outpatient OERC prescriptions seen in the palliative care clinic. Eighty-two charts were reviewed with 66 included. Overall mean pain scores at both follow-ups were lower than those at baseline (-0.7 ± 2.1; -1.1 ± 2.4). Results were statistically significant between first and second-reported pain scores versus baseline (p = 0.009; 0.012) but clinically insignificant, defined as a ≥ 2-point change in numeric pain scores. Most patients discontinued OERC at the first or second follow-up (35; 53%), and 12.1% of patients who started OERC were prescribed OERC at the end of the study. There were no significant variables identified to influence pain scores either statistically or clinically. Further studies are needed to determine the long-term efficacy and safety in cancer palliative-care patients.


Assuntos
Neoplasias , Oxicodona , Humanos , Oxicodona/uso terapêutico , Analgésicos Opioides/uso terapêutico , Manejo da Dor/métodos , Cuidados Paliativos , Estudos Retrospectivos , Preparações de Ação Retardada/uso terapêutico , Dor/tratamento farmacológico , Dor/etiologia , Neoplasias/complicações , Neoplasias/tratamento farmacológico
2.
Clin J Oncol Nurs ; 21(5): 573-580, 2017 10 01.
Artigo em Inglês | MEDLINE | ID: mdl-28945712

RESUMO

BACKGROUND: A diagnosis of cancer is a stressful, difficult, and life-altering event. Breaking bad news is distressing to patients and families and is often uncomfortable for the nurse delivering it. Evidence-based communication models have been developed and adapted for use in clinical practice to assist nurses with breaking bad news.

. OBJECTIVES: The purpose of this article is to provide an overview on breaking bad news and to review the utility of the SPIKES and PEWTER evidence-based communication models for oncology nurses.
. METHODS: Perceptions of breaking bad news from the nurse and patient perspectives, as well as barriers and consequences to effective communication, will be presented. Clinical examples of possible situations of breaking bad news will demonstrate how to use the SPIKES and PEWTER models of communication when disclosing bad news to patients and their families.
. FINDINGS: By using the evidence-based communication strategies depicted in this article, oncology nurses can support the delivery of bad news and maintain communication with their patients and their patients' families in an effective and productive manner.


Assuntos
Comunicação , Enfermagem Baseada em Evidências , Modelos de Enfermagem , Enfermagem Oncológica , Humanos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...